Canadian ciprofloxacin susceptibility study: comparative study from 15 medical centers. Canadian Ciprofloxacin Study Group (original) (raw)

Abstract

We tested 4,507 microorganisms, from 15 Canadian medical centers, against ciprofloxacin and several other antimicrobial agents to determine the in vitro susceptibilities. Overall, susceptibility of members of the family Enterobacteriaceae to ciprofloxacin was 97%; Moraxella and Haemophilus spp. had susceptibilities of 98 and 99%, respectively; and P. aeruginosa and S. aureus had susceptibilities of 79 and 96%, respectively.

Full Text

The Full Text of this article is available as a PDF (251.9 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Chamberland S., L'Ecuyer J., Lessard C., Bernier M., Provencher P., Bergeron M. G. Antibiotic susceptibility profiles of 941 gram-negative bacteria isolated from septicemic patients throughout Canada. The Canadian Study Group. Clin Infect Dis. 1992 Oct;15(4):615–628. doi: 10.1093/clind/15.4.615. [DOI] [PubMed] [Google Scholar]
  2. Coronado V. G., Edwards J. R., Culver D. H., Gaynes R. P., National Nosocomial Infections Surveillance (NNIS) System Ciprofloxacin resistance among nosocomial Pseudomonas aeruginosa and Staphylococcus aureus in the United States. Infect Control Hosp Epidemiol. 1995 Feb;16(2):71–75. doi: 10.1086/647059. [DOI] [PubMed] [Google Scholar]
  3. Felmingham D., O'Hare M. D., Robbins M. J., Wall R. A., Williams A. H., Cremer A. W., Ridgway G. L., Grüneberg R. N. Comparative in vitro studies with 4-quinolone antimicrobials. Drugs Exp Clin Res. 1985;11(5):317–329. [PubMed] [Google Scholar]
  4. Hoban D. J., Jones R. N. Canadian ofloxacin susceptibility study: a comparative study from 18 medical centers. Canadian Ofloxacin Study Group. Chemotherapy. 1995 Jan-Feb;41(1):34–38. doi: 10.1159/000239321. [DOI] [PubMed] [Google Scholar]
  5. Louie T. J. Ciprofloxacin: an oral quinolone for the treatment of infections with gram-negative pathogens. Committee on Antimicrobial Agents. Canadian Infectious Disease Society. CMAJ. 1994 Mar 1;150(5):669–676. [PMC free article] [PubMed] [Google Scholar]
  6. Parry M. F., Panzer K. B., Yukna M. E. Quinolone resistance. Susceptibility data from a 300-bed community hospital. Am J Med. 1989 Nov 30;87(5A):12S–16S. doi: 10.1016/0002-9343(89)90012-0. [DOI] [PubMed] [Google Scholar]
  7. Raviglione M. C., Boyle J. F., Mariuz P., Pablos-Mendez A., Cortes H., Merlo A. Ciprofloxacin-resistant methicillin-resistant Staphylococcus aureus in an acute-care hospital. Antimicrob Agents Chemother. 1990 Nov;34(11):2050–2054. doi: 10.1128/aac.34.11.2050. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Shalit I., Berger S. A., Gorea A., Frimerman H. Widespread quinolone resistance among methicillin-resistant Staphylococcus aureus isolates in a general hospital. Antimicrob Agents Chemother. 1989 Apr;33(4):593–594. doi: 10.1128/aac.33.4.593. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Toye B. W., Scriver S. R., Low D. E. Canadian survey of antimicrobial resistance in Klebsiella spp. and Enterobacter spp. The Canadian Antimicrobial Resistance Study Group. J Antimicrob Chemother. 1993 Nov;32 (Suppl B):81–86. doi: 10.1093/jac/32.suppl_b.81. [DOI] [PubMed] [Google Scholar]
  10. Walker R. C., Wright A. J. The fluoroquinolones. Mayo Clin Proc. 1991 Dec;66(12):1249–1259. doi: 10.1016/s0025-6196(12)62477-x. [DOI] [PubMed] [Google Scholar]
  11. Wiedemann B., Zühlsdorf M. T. Resistance development to fluoroquinolones in Europe. Am J Med. 1989 Nov 30;87(5A):9S–11S. doi: 10.1016/0002-9343(89)90011-9. [DOI] [PubMed] [Google Scholar]